Navigation

Mountainview Consulting Group
Home

Mountainview Menu

  • Home
  • Services
    • Endorsements
  • About
  • Contact
  • Books
    • In This Moment
    • Inside This Moment
    • Behavioral Consultation and Primary Care, Second Edition
    • Behavioral Consultation and Primary Care
    • Brief Interventions for Radical Change
    • Real Behavior Change in Primary Care
    • The Mindfulness & Acceptance Workbook for Depression
  • Videos
    • FACT
    • Primary Care How-To
    • Primary Care Lectures
  • News
  • Blog
    • Acceptance and Commitment Therapy
    • Primary Care Behavioral Health
Return to Content

U.S. FDA to Pull Opana ER, Powerful Opioid from Market

By Bridget Beachy on June 10, 2017 in Healthcare News

“The US Food and Drug Administration said Thursday that drugmaker Endo Pharmaceuticals must remove its powerful opioid painkiller Opana ER from the market.”  Follow the link for more details! Stay strong FDA.

http://www.cnn.com/2017/06/08/health/fda-opioid-opana-er-bn/index.html?sr=fbCNN060917fda-opioid-opana-er-bn0230AMVODtopLink&linkId=38513964

Dr. Beachy Completes 1 year Fellowship
#MCG on Social Media

Categories

  • Acceptance and Commitment Therapy
  • Healthcare News
  • News
  • Primary Care Behavioral Health

Recent Posts

  • Dr. Robinson earns “Outstanding Contributions to the PCBH Model Award” at CFHA 2017
  • Don’t tape over your “check engine” light! Depression signals growth opportunities
  • Dr. Robinson presented with APA Div. 38’s Outstanding Contributions Award
  • Drs. Robinson & Bauman Co-Author Book Chapter on Persistent Pain
  • #MCG’s Dr. Polaha in The Atlantic!

© 2019 Mountainview. All Rights Reserved.

Hosted locally at Portland's Host Pond Web Hosting